Dyne Therapeutics, Inc. (DYN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $17.77: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 5.42; Below-average business quality.
Dyne Therapeutics is a clinical-stage biotech developing therapies for genetically driven neuromuscular diseases via its FORCE platform, which uses an antibody targeting transferrin receptor 1 to deliver therapeutic payloads to muscle. Lead programs are z-rostudirsen (DMD exon... Read more
Sell if holding. Engine safety override at $17.77: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 5.42; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.6/10, moderate confidence.
Passes 5/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinez-rostudirsen10-K Item 1A: 'particularly as we advance the clinical development of z-rostudirsen and z-basivarsen'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 5.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $17.77: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.6/10 and A.R:R 8.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Elevated put/call ratio: 5.42; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $16.77. Score 4.6/10, moderate confidence.
Take-profit target: $34.37 (+93.4% upside). Prior stop was $16.77. Stop-loss: $16.77.
Concentration risk — Pipeline: z-rostudirsen; Quality below floor (1.6 < 4.0).
Dyne Therapeutics, Inc. trades at a P/E of N/A (forward -5.7). TrendMatrix value score: 9.0/10. Verdict: Sell.
20 analysts cover DYN with a consensus score of 4.2/5. Average price target: $38.
What does Dyne Therapeutics, Inc. do?Dyne Therapeutics is a clinical-stage biotech developing therapies for genetically driven neuromuscular diseases via...
Dyne Therapeutics is a clinical-stage biotech developing therapies for genetically driven neuromuscular diseases via its FORCE platform, which uses an antibody targeting transferrin receptor 1 to deliver therapeutic payloads to muscle. Lead programs are z-rostudirsen (DMD exon 51 skipping, BLA planned Q2 2026) and z-basivarsen (DM1); no products commercialized yet.